Coherus Oncology (CHRS) Other Non-Current Liabilities (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Other Non-Current Liabilities data on file, last reported at $17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 45.78% year-over-year to $17.0 million; the trailing twelve-month figure through Mar 2026 stood at $17.0 million (down 45.78% YoY), and the FY2025 full-year result was $1.8 million, down 93.81% from the prior year.
• Other Non-Current Liabilities grew to $17.0 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $31.3 million in Q1 2025 to a low of $102000.0 in Q1 2022.
• A 5-year average of $8.5 million and a median of $1.8 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 27053.92% in 2024 and slumped 93.81% in 2025, its largest moves.
• Tracing CHRS's Other Non-Current Liabilities over 5 years: stood at $3.5 million in 2022, then surged by 262.3% to $12.6 million in 2023, then surged by 133.49% to $29.3 million in 2024, then slumped by 93.81% to $1.8 million in 2025, then jumped by 834.77% to $17.0 million in 2026.
• Business Quant data shows CHRS's Other Non-Current Liabilities at $17.0 million in Q1 2026, $1.8 million in Q4 2025, and $102000.0 in Q3 2025.